Bristol-Myers Squibb Company with ticker code (BMY) have now 22 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The target price High/Low ranges between $90.00 and $42.00 and has a mean target at $62.32. Now with the previous closing price of $52.11 this would indicate that there is a potential upside of 19.6%. The 50 day moving average now sits at $52.12 and the 200 day MA is $61.22. The market capitalization for the company is 105.79B. The stock price for the company is currently $51.99 USD
The potential market cap would be $126,514,229,231 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 13.2, revenue per share of $21.51 and a 5.59% return on assets.
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
